MarketBeat is an American financial media company headquartered in Sioux Falls, South Dakota, founded in 2011 by Matthew Paulson as Analyst Ratings Network before rebranding in 2015. The company operates an online platform that delivers real-time financial data, market analysis, and news, aiming to empower individual investors with tools to make informed trading decisions.
Tenaya Therapeutics (NASDAQ:TNYA) expects to provide regulatory and development updates in the fourth quarter for its two cardiac gene therapy programs and its small-molecule candidate TN-301, Chief Financial Officer Eric Hyllengren said during a Canaccord discussion.
Hyllengren, who said he had be
Tonix Pharmaceuticals (NASDAQ:TNXP) is focusing its near-term strategy on the commercial launch of TONMYA for fibromyalgia while advancing development programs in Lyme disease prevention and major depressive disorder, Chief Executive Officer Seth Lederman said during a Canaccord Genuity conference p
Tandem Diabetes Care (NASDAQ:TNDM) highlighted its plans to expand insulin pump adoption through a shift to pharmacy distribution in the U.S., direct sales in additional international markets and upcoming product launches, including a tubeless version of its Tandem Mobi pump.
Speaking at Canaccord’
TransMedics Group (NASDAQ:TMDX) outlined its growth strategy at Canaccord Genuity’s 46th Annual Global Growth Conference, highlighting investments in kidney transplantation, European expansion, next-generation technology and broader adoption in heart and lung transplantation.
Waleed Hassanein, Tran
TriSalus Life Sciences (NASDAQ:TLSI) outlined its commercial expansion, product pipeline and clinical-evidence strategy during Canaccord Genuity’s Global Growth Conference, with management emphasizing the company’s pressure-enabled delivery technology for solid-tumor treatments.
President and CEO M
Gentherm (NASDAQ:THRM) outlined plans to diversify beyond light-vehicle thermal comfort products, expand margins and complete its combination with Modine Performance Technologies, which management expects to close in early fourth quarter.
Speaking at a JPMorgan event, President and CEO Bill Presley
908 Devices outlined its strategy to focus exclusively on handheld chemical and drug detection technologies for public safety and defense markets, following the divestiture of its life-sciences business line about 15 months ago.
Speaking at a Canaccord Genuity event, President, CEO and Co-Founder K
Atlassian (NASDAQ:TEAM) said its cloud business momentum continued through the fourth quarter of fiscal 2026, supported by customer upgrades, cross-selling activity and expanding paid seats across both software development and non-technical teams.
Speaking at a KeyBanc conference, Martin Lam, Atlas
Yalla Group (NYSE:YALA) reported second-quarter 2026 revenue of $82.6 million, exceeding the upper end of its prior guidance, as growth in game services and a recovery in flagship products helped offset pressure on its core business from regional geopolitical events.
Revenue declined from $84.6 mil
Stoke Therapeutics (NASDAQ:STOK) said its Phase III EMPEROR study of zorevunersen for Dravet syndrome has enrolled 162 patients, exceeding its target enrollment of 150, with no patient discontinuations reported to date.
Speaking at a Canaccord Genuity event, Chief Executive Officer Ian Smith said t
Scholar Rock (NASDAQ:SRRK) CEO David Hallal said the company is preparing for a September 30 FDA decision date for apitegromab, its investigational treatment for spinal muscular atrophy, or SMA, following a resubmitted biologics license application supported by an alternate fill-finish manufacturing
XP (NASDAQ:XP) reported second-quarter 2026 gross revenue of BRL 5.1 billion, up 8% from a year earlier, as growth in equities, fund-platform fees and corporate banking partly offset pressure from credit-market volatility and weaker primary debt offerings.
Adjusted earnings before taxes rose 15% ye
BHP Group (NYSE:BHP) reported what Chief Executive Officer Brandon Craig described as a strong financial year, supported by record production in Western Australia iron ore, strong performance at the Escondida copper mine in Chile, resilient iron ore prices and high copper prices.
Chief Financial Of
Fabrinet (NYSE:FN) reported record fourth-quarter results for fiscal 2026, with revenue rising 45% year over year to $1.316 billion and non-GAAP earnings per share reaching $4.10, above the company’s guidance range. The fiscal fourth quarter ended June 26, 2026.
For the full fiscal year, revenue in
Rio2 (TSE:RIO) executives said operations at its Phoenix Gold project have been disrupted by two severe winter storms, delaying the company’s expected progress toward steady-state throughput of more than 20,000 tonnes per day. Management said the project lost about two weeks of production during a J
DocGo (NASDAQ:DCGO) reported second-quarter revenue of $73.4 million, down from $80.4 million a year earlier, as the company continued to wind down migrant-related projects. Excluding migrant-related revenue, revenue rose 19% year over year, while revenue from business lines operating in both period
Duos Technologies Group (NASDAQ:DUOT) said its second-quarter results reflected the completion of its shift from rail technology toward edge data centers, AI infrastructure and technology solutions, supported by divestitures, new customer agreements and a substantially larger cash balance.
Chief Ex
Enovix (NASDAQ:ENVX) said its strategy, product roadmap, customer programs and qualification schedules remain unchanged following the resignation of CEO Raj, as the company appointed Chief Financial Officer Ryan Benton as interim CEO and named Executive Chairman T.J. Rodgers to a more active operati
Biosig Technologies (NASDAQ:STEX) provided a second-quarter update on its Streamex tokenization platform, reporting its first gold lease income while outlining plans to expand distribution for its yield-bearing gold token, GLDY, and launch a permissionless token, GLDC.
Chief Executive Officer and c
New Era Energy & Digital (NASDAQ:NUAI) said it advanced permitting, land acquisition and power planning during the second quarter as it works to develop its Texas Critical Data Centers, or TCDC, campus near Odessa, Texas.
Chairman and Chief Executive Officer Charlie Nelson said the company concentr
Penguin Solutions (NASDAQ:PENG) is positioning its business around a full-stack “AI factory” platform that combines infrastructure, memory technology, software and managed services, Senior Vice President of Global Marketing Mark Adams said during Rosenblatt Securities’ Sixth Annual Age of AI Scaling
Pegasystems (NASDAQ:PEGA) CTO Don Schuerman said enterprise customers are shifting their artificial intelligence priorities from demonstrating AI adoption to pursuing measurable business value, with a focus on customer experience, efficiency, compliance and predictable operating costs.
Speaking at
Strategy (NASDAQ:MSTR) executives said the company’s near-term priority is strengthening its digital credit business, particularly its STRC preferred instrument, rather than repurchasing common shares or paying a dividend on MSTR stock.
During a live investor Q&A moderated by Natalie Brunell, F
Commodity ETFs BCI, PDBC, and COM have posted strong 2026 gains amid inflation and geopolitical pressures, though returns, fees, and yields vary widely across each fund's strategy.
Insight Molecular Diagnostics discussed the potential use of donor-derived cell-free DNA testing in heart transplant surveillance during a virtual session featuring transplant cardiologist Dr. Max Liebo of Loyola University.
Chief Executive Officer Josh Riggs said the company’s GraftAssureDx test i
As actively managed ETFs gain market share, CGDV, FLSP and RLY stand out with distinct strategies, notable year-to-date returns, and dividend yields ranging from 1.14% to 2.99%.
The JPMorgan International Value ETF (JIVE) has outpaced the S&P 500 this year, offering low-volatility, diversified international exposure with a 1.22% yield and rising institutional demand.
Fortinet (NASDAQ:FTNT) CFO Christiane Ohlgart said the cybersecurity company’s second-quarter performance was supported by broad-based global demand, accelerating hardware sales and growing adoption of secure networking and unified secure access service edge, or SASE, offerings.
Speaking at a fires
Birkenstock topped Q3 revenue estimates and raised FY2026 guidance, but shares fell after L Catterton's $1 billion secondary offering, partly offset by a $500 million share buyback.
Eyepoint Pharmaceuticals (NASDAQ:EYPT) reported topline results from LUGANO, the first of two Phase III trials evaluating DURAVYU, a vorolanib intravitreal insert, in patients with wet age-related macular degeneration, or wet AMD. The study did not meet its primary non-inferiority endpoint in the fu
Erdene Resource Development (TSE:ERD) reported higher second-quarter gold production and lower unit costs as the Bayan Khundii Gold Mine in southwestern Mongolia continued its ramp-up toward steadier operations.
The Bayan Khundii mine, held through the 50/50 Erdene Mongol joint venture with Mongoli
D-Wave Quantum shares are recovering after a mixed Q2 2026 report, as investors weigh a small Canadian grant against the need for repeatable revenue, new customers, and progress toward profitability.
Taiwan Semiconductor insiders are ramping up open-market share purchases as strong Q2 guidance, 2nm demand, and AI-driven analyst upgrades support a bullish outlook for TSM stock.
HIVE Digital Technologies (NASDAQ:HIVE) reported fiscal first-quarter 2027 revenue of $79.1 million, up 73% from $45.6 million a year earlier and 10% sequentially, as the company expanded its Bitcoin mining operations and continued building its high-performance computing, or HPC, and artificial inte
With CrowdStrike shares trading above analyst targets, DataDog, Qualys, and Guidewire offer AI cybersecurity exposure with strong earnings, guidance increases, and analyst support.
U-Haul, Avis Budget, Public Storage, Extra Space Storage and CubeSmart offer exposure to migration trends, with varying growth, dividend yields and analyst price targets.
argenx (NASDAQ:ARGX) reported positive top-line results from its Phase III ALKIVIA trial of VYVGART Hytrulo in autoimmune myositis, meeting its primary endpoint in a combined population of patients with immune-mediated necrotizing myopathy, or IMNM, and dermatomyositis, or DM.
The study evaluated e
Cosan (NYSE:CSAN) reported a narrower net loss for the second quarter of 2026 as the Brazilian conglomerate advanced debt-reduction, divestment and cost-cutting efforts designed to simplify its holding-company structure.
Net loss totaled BRL 320 million for the quarter, an improvement from the prio
PagSeguro Digital (NYSE:PAGS) reported second-quarter results marked by continued growth in banking engagement, credit balances and deposits, while management said it maintained its full-year targets despite a more challenging macroeconomic environment and elevated interest rates in Brazil.
Total p
Syntec Optics (NASDAQ:OPTX) reported record second-quarter revenue for 2026, returning to operating and net profitability as sales increased across its medical, defense, consumer and communications markets.
Revenue for the quarter totaled approximately $8.3 million, up 26% from approximately $6.6 m
Freightos (NASDAQ:CRGO) reported second-quarter 2026 revenue of $7.7 million, up 3% from a year earlier and above the company’s expectations, as growth in platform revenue offset a decline in solutions revenue. The company also said its adjusted EBITDA loss narrowed to $2 million, its lowest reporte
DeFi Development (NASDAQ:DFDV) used its second-quarter 2026 earnings update call to emphasize its strategy of building long-term Solana per-share exposure through validator operations, on-chain deployment and leverage, while simplifying its capital structure and reducing noncore complexity.
Chief E
BlackRock, DLocal, Chevron, Williams Companies, and MetLife pay solid dividends and carry favorable analyst ratings, offering income investors growth exposure and price target upside.
Quantum Computing Inc. and Infleqtion posted strong revenue growth but widening losses in Q2 earnings, leaving IonQ ahead of smaller rivals and D-Wave as quantum stocks diverge.
Mobileye, Ondas Holdings and Palladyne AI have each fallen under $10, but for different reasons, ranging from leadership uncertainty to dilution concerns to thin analyst coverage.
H World Group (NASDAQ:HTHT) reported second-quarter revenue growth and higher profitability, supported by expansion in China, improving room rates and continued growth in its managed and franchised hotel business.
Group revenue rose 10.8% year over year to RMB7.1 billion in the second quarter, Chie
Fulcrum Therapeutics (NASDAQ:FULC) has entered into an all-stock merger agreement with privately held Slate Medicines, a migraine-focused biotechnology company, in a transaction expected to close in the fourth quarter of 2026, subject to stockholder approval and customary closing conditions.
Alex S
BitFuFu (NASDAQ:FUFU) reported second-quarter 2026 results marked by lower cloud-mining revenue and a net loss amid weaker Bitcoin prices, while management emphasized growth in self-mining production, expansion of hosting services and investments in more efficient equipment.
Chairman and CEO Leo Lu
Buffered ETFs PJUL, BSEP, and QBUF offer investors varying levels of downside protection and capped upside tied to the S&P 500 or Nasdaq-100, using options-based strategies.
JFrog's strong Q2 results and raised guidance sparked widespread analyst price target increases, with technical trends and cloud growth pointing to potential new highs for FROG stock.
Sandisk (NASDAQ:SNDK) used its investor event to outline a strategy centered on NAND technology scaling, longer-term customer agreements, AI data-center demand and shareholder cash returns.
Chairman and Chief Executive Officer David Goeckeler said the company has spent the past 18 months strengthen
Solid Power (NASDAQ:SLDP) said it is advancing a capital-light strategy centered on supplying sulfide solid electrolyte materials for all-solid-state batteries, while targeting increased production capacity, deeper partnerships and expansion into markets beyond electric vehicles.
During a JPMorgan
Sagimet Biosciences (NASDAQ:SGMT) plans to begin a Phase III study of its oral fatty acid synthase, or FASN, inhibitor denifanstat in moderate-to-severe acne within the next several months, following positive results from a China-based Phase III trial conducted by partner Ascletis, company executive
SailPoint (NASDAQ:SAIL) outlined how identity governance and administration systems could help government organizations manage machinery-of-government changes, or MOGs, which the company described as the public-sector equivalent of corporate reorganizations.
In the first of a four-part government-f
Rhythm Pharmaceuticals (NASDAQ:RYTM) is expanding commercialization of its rare-disease obesity treatment IMCIVREE while advancing additional melanocortin-4 receptor, or MC4R, agonists through development, Chief Financial Officer Hunter Smith said during a Canaccord Genuity fireside chat.
Smith sai
Recursion Pharmaceuticals (NASDAQ:RXRX) is using artificial intelligence to generate and analyze biological data in an effort to improve drug discovery, advance internal therapeutic programs and support collaborations with larger pharmaceutical companies, CFO and President of Recursion U.K. Ben Tayl
Rumble (NASDAQ:RUM) is positioning its recently combined operations as an AI compute infrastructure business with a substantial 2027 power pipeline, while continuing to operate its established video platform separately.
Speaking at an event with Canaccord Genuity Equity Research Senior Analyst King
Repay (NASDAQ:RPAY) executives said the company is positioning itself as a broader provider of consumer bill payment, bill presentment and communications services following its acquisition of KUBRA, while targeting an acceleration in organic growth and using cash flow to reduce leverage.
Speaking a
Roper Technologies (NASDAQ:ROP) is pursuing a strategy centered on long-term free-cash-flow-per-share growth, portfolio collaboration and acquisitions of vertical-market software businesses, while increasingly deploying artificial intelligence across its operations and products, Chief Financial Offi
RenovoRx (NASDAQ:RNXT) executives and physician speakers discussed the treatment landscape for locally advanced pancreatic cancer, the company’s Trans-Arterial Micro-Perfusion, or TAMP, platform, and commercialization progress for its RenovoCath delivery device during a webinar hosted by JonesTradin
Real Brokerage (NASDAQ:REAX) Founder and CEO Tamir Poleg said the company had grown to more than 36,000 agents across the U.S. and Canada, positioning its technology-driven brokerage model for further expansion as it pursues its acquisition of RE/MAX Holdings.
Speaking at an Oppenheimer event, Pole
Avita Medical (NASDAQ:RCEL) reported second-quarter 2026 revenue of $21.7 million, up 13% sequentially from $19.3 million in the first quarter and 18% from $18.4 million a year earlier, as the wound-care company cited growth across its product portfolio and in U.S. and international markets.
Presid
Avita Medical (NASDAQ:RCEL) expects continued sequential revenue growth and aims to reach cash flow breakeven in the fourth quarter of 2025, President and CEO Cary Vance said at the Canaccord 46th Annual Boston Growth Conference.
Vance, who has been CEO for about 10 months after previously serving
Rani Therapeutics (NASDAQ:RANI) outlined its strategy to expand the use of its RaniPill oral biologic-delivery platform through a mix of technology partnerships, selectively licensed product programs and investments in manufacturing capacity.
Chief Executive Officer Talat Imran described the clinic
QuickLogic (NASDAQ:QUIK) is targeting aerospace, defense and other long-life infrastructure applications as it expands its programmable logic offerings, President and CEO Brian Faith said during a Canaccord Genuity discussion.
Faith described programmable logic as a semiconductor segment experienci
Quanterix (NASDAQ:QTRX) CEO Everett Cunningham said the company is repositioning its commercial organization and investing in diagnostics and clinical-trial capabilities following the integration of Akoya Biosciences, while acknowledging continued pressure in academic, government and biopharma marke
Qualys (NASDAQ:QLYS) executives said the company’s second-quarter performance reflected growing customer demand for vulnerability remediation, patch management and Enterprise TruRisk Management, or ETM, while positioning newer products as potential drivers of longer-term growth.
During an investor
The Metals Company faces a licensing delay to October, but analysts remain optimistic as revenue could begin in late 2027 amid growing US national security interest in deep-sea mining.
Palvella Therapeutics (NASDAQ:PVLA) is advancing topical therapies for serious rare skin diseases and vascular malformations that lack FDA-approved treatments, with its lead candidate, QTORIN rapamycin, moving toward a planned New Drug Application submission for microcystic lymphatic malformations.
OneSpaWorld posted record Q2 revenue and adjusted earnings, raised full-year guidance, and retains an analyst Buy rating, though it remains heavily dependent on the cruise industry.
PTC Therapeutics (NASDAQ:PTCT) plans to acquire the ST-920 Fabry disease gene therapy asset through a competitive bankruptcy auction, positioning the company to add a potential one-time treatment to its rare disease portfolio while using its existing global commercial and regulatory infrastructure.
Meta Platforms and Tesla show improving RSI readings after recent selloffs, with both Magnificent Seven stocks facing earnings volatility but analysts still forecasting double-digit upside ahead.
People Incorporated Common Stock (NASDAQ:PPLI) is focusing its capital allocation on its MGM minority stake and its People media business while seeking new homes for several non-core assets, Chief Financial Officer Tim Quinn said during a fireside chat.
Quinn said the former IAC has identified MGM
